Momenta ( Momenta )

Momenta

Momenta's picture

Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and follow-on biologics as well as facilitate the discovery of novel drugs. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline of innovative generic and novel drugs.

Momenta press release, blog etc

05/17/2018 - 11:48 Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
05/10/2018 - 05:38 Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
02/13/2018 - 00:29 Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa (glatiramer acetate injection) 40 mg/mL
02/08/2018 - 08:52 Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference
01/30/2018 - 10:11 Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa (glatiramer acetate injection) Fill/Finish Manufacturer
01/05/2018 - 08:57 Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
01/03/2018 - 14:39 Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)
12/28/2017 - 05:31 Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference
11/08/2017 - 06:36 Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference
11/01/2017 - 06:36 Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)
10/02/2017 - 13:10 Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer
08/30/2017 - 07:43 Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference
07/21/2017 - 11:39 Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
06/07/2017 - 10:46 Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference
06/01/2017 - 11:36 Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer
05/10/2017 - 16:42 UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
04/26/2017 - 09:50 Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference
02/28/2017 - 08:21 Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference